Semi-Annual Consolidated Statement Of Cash Flows

Carna Biosciences, Inc. - Filing #7613644

Concept As at
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
As at
2020-12-31
2020-01-01 to
2020-12-31
2020-01-01 to
2020-12-31
As at
2019-12-31
Semi-annual consolidated statement of cash flows
Statement of cash flows
Cash flows from operating activities
Profit (loss) before income taxes
-558,351,000 JPY
-532,499,000 JPY
-1,121,738,000 JPY
-1,102,487,000 JPY
Depreciation
19,164,000 JPY
12,410,000 JPY
Impairment losses
9,507,000 JPY
26,390,000 JPY
Interest expenses
3,925,000 JPY
7,373,000 JPY
Foreign exchange losses (gains)
-10,029,000 JPY
2,372,000 JPY
Decrease (increase) in trade receivables
-1,110,099,000 JPY
-13,951,000 JPY
Decrease (increase) in inventories
-5,966,000 JPY
-5,107,000 JPY
Increase (decrease) in trade payables
776,000 JPY
-1,655,000 JPY
Other, net
1,065,000 JPY
-33,710,000 JPY
Subtotal
-1,582,110,000 JPY
-1,120,158,000 JPY
Interest paid
-4,097,000 JPY
-7,119,000 JPY
Net cash provided by (used in) operating activities
-1,536,612,000 JPY
-1,260,972,000 JPY
Cash flows from investing activities
Purchase of property, plant and equipment
-41,522,000 JPY
-64,737,000 JPY
Other, net
JPY
-1,578,000 JPY
Net cash provided by (used in) investing activities
-41,677,000 JPY
-70,433,000 JPY
Cash flows from financing activities
Proceeds from long-term borrowings
300,000,000 JPY
JPY
Repayments of long-term borrowings
-161,897,000 JPY
-270,972,000 JPY
Redemption of bonds
-28,028,000 JPY
-28,028,000 JPY
Net cash provided by (used in) financing activities
1,064,987,000 JPY
724,423,000 JPY
Other, net
-3,080,000 JPY
JPY
Effect of exchange rate change on cash and cash equivalents
31,994,000 JPY
-8,931,000 JPY
Net increase (decrease) in cash and cash equivalents
-481,307,000 JPY
-615,914,000 JPY
Cash and cash equivalents
3,817,834,000 JPY
4,299,142,000 JPY
4,915,056,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.